Abstract
AbstractThere is a paucity of genetic characterization in people with Parkinson’s disease (PD) of Latino and Afro-Caribbean descent. Screening LRRK2 and GBA variants in 32 New Yorkers of Puerto Rican ethnicity with PD and in 119 non-Hispanic-non-Jewish European PD cases revealed that Puerto Rican participants were more likely to harbor the LRRK2-p.G2019S variant (15.6% vs. 4.2%, respectively). Additionally, whole exome sequencing of twelve Puerto Rican and Dominican PD participants was performed as an exploratory study.
Funder
National Parkinson Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Neurology (clinical),Neurology
Reference30 articles.
1. Cook Shukla, L., et al. Parkinson Disease Overview. 2004 May 25 [Updated 2019 Jul 25]. in GeneReviews® [Internet] (eds Adam, M. P., Ardinger, H. H., Pagon, R. A., et al.) (University of Washington, 1993–2021).
2. Ortega, R. A. et al. Association of dual LRRK2 G2019S and GBA variations with Parkinson disease progression. JAMA Netw. Open 4, e215845 (2021).
3. Nishioka, K. et al. Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. Neurosci. Lett. 477, 57–60 (2010).
4. Ruiz-Martínez, J. et al. Penetrance in Parkinson’s disease related to the LRRK2 R1441G mutation in the Basque Country (Spain). Mov. Disord. 25, 2340–2345 (2010).
5. Cruz-Vicente, P., Passarinha, L. A., Silvestre, S. & Gallardo, E. Recent developments in new therapeutic agents against Alzheimer and Parkinson diseases: in-silico approaches. Molecules. 26, 2193 (2021).